Vanadis NIPT

Vanadis NIPT Vanadis NIPT Pregnancy Health


VANADIS® NIPT
Vanadis is the next-generation noninvasive prenatal test developed to help pregnant women assess the risk of their fetus carrying a trisomy.
 
About Vanadis® NIPT
 
We now know that fragments of your baby’s DNA, originating from your placenta, circulate in your blood during pregnancy. DNA is the substance that our chromosomes are made of, and it contains our genetic information. By analyzing the baby’s DNA found in your blood, the Vanadis® test is able to quantify the risk that your baby is affected by chromosomal conditions such as Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), and Patau Syndrome (Trisomy 13).
 
Simple
Performed from a simple blood sample
 
Early
Screening can be performed as early as 10 weeks gestation
 
Quality
The quality of the system is ensured at each step of the workflow.
 
Accurate
Accurate screening for the three most common trisomy disorders: Trisomy 21, 18 and 13
 
Safe
Poses no risk of miscarriage to your pregnancy
 
Why have NIPT?
 
Prenatal screening is offered to pregnant women because all pregnancies have a small chance for a genetic disorder, regardless of maternal age, family history, or personal health. Screening is traditionally done through routine tests such as analyzing maternal blood and/or performing an ultrasound.
Who can have the NIPT test?
 
Any pregnant woman who wants to know whether there is a risk her baby carries a chromosomal condition such as Down Syndrome can be screened using the Vanadis® test.
 
Check out our latest article
 
 
Clinical validation of a novel automated cellę\free DNA screening assay...
 
Imaging single DNA molecules for high precision NIPT
 
Vanadis® NIPT: An Automated System for High-Precision...
Please consult your doctor for more information
Please leave your enquiry here, we will reply as soon as possible.
Name*  
Company Name  
Product Interested  
Quantity  
Email*  
Contact No.*  
Attachment  
*only support gif, jpeg, jpg, png, pdf
Messages*  

Switch to Mobile Version
Subscribe Newsletter